for intravenous use Initial U.S. Approval: 2022
As specified in the prescribing information, tremelimumab-actl injection is indicated for the treatment of unresectable hepatocellular carcinoma (uHCC) and non-small cell lung cancer (NSCLC). IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
Facts about tremelimumab-actl injection
Approval Date: 10/21/2022
Proprietary Name: Imjudo
Active Ingredient(s): tremelimumab-actl
FDA-approved use: To treat unresectable hepatocellular carcinoma
Injection: 25 mg/1.25 mL (20 mg/mL) solution in a single-dose vial.
Injection: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial.
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “tremelimumab-actl injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For tremelimumab-actl injection
Approved accessible "tremelimumab-actl injection"
Imjudo (tremelimumab-actl) injection, which was first approved in 2022 to treat unresectable hepatocellular carcinoma, was later approved in the same year in combination with other therapies to treat adults with metastatic non-small cell lung cancer with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Imjudo (tremelimumab-actl) injection to treat unresectable hepatocellular carcinoma, the most common type of liver cancer, in combination with Imfinzi.
How can 1 go about obtaining tremelimumab-actl injection?
If tremelimumab-actl injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
IMJUDO (tremelimumab-actl) injection, for intravenous use Initial U.S. Approval: 2022
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398